New Israeli test to eliminate painful prostate cancer biopsy

News » Science & Technology

< /p>

On the occasion of World Cancer Day, the International Agency for Research on Cancer of the World Health Organization has published a global cancer forecast.

According to these data, in 2040, prostate cancer, the most common malignant tumor among men, will be diagnosed in approximately 2.43 million men worldwide, compared to today's number of patients, which is approximately 1.4 million.

In Israel, according to the World Health Organization, about 5,254 men will develop prostate cancer in 2040. In 2023, the number of patients is about 2,600 people. Thus, in fact, within 17 years, the number of patients with prostate cancer in Israel will double.

In addition, about 740,000 men worldwide will die of prostate cancer in 2040, and about 1,070 Israelis will die in Israel in 2040. To date, according to the World Health Organization, about 375 thousand men die of prostate cancer in the world, and according to the Cancer Society, 530 men have died in Israel over the past year.

According to the Ministry of Health, prostate cancer accounts for about 21% of all invasive tumors among Jewish men, about 11% among Arab men, and about 8.4% of cancer deaths among men.

Scientific evidence shows about the existence of a trend towards a decrease in cancer mortality with early diagnosis. Of note, the Ministry of Health just recently approved a revolutionary blood test to accurately predict the presence of aggressive prostate cancer, which greatly improves the early detection of patients.

The blood test is called IsoPSA and it avoids more than 50% of biopsies due to precise decoding technology that identifies a change in protein structure that occurs exclusively in a cancerous tumor.

Professor Ofer Nativ, Senior Urologist at Elisha Hospital, former Director of the Department of Urology at Bnei Zion Medical Center, explains: “Due to the predictive power of the test, we can predict the presence of aggressive prostate cancer and save the patient from a painful biopsy. Therefore, for every man in Israel with a PSA level above 4, if he is over 50 years old and his urologist is already considering a biopsy, it is very important to check compatibility with the IsoPSA test, which has proven to be reliable and accurate. Thanks to his clear response, we urologists only send men for biopsy who have aggressive prostate cancer.”

The test is introduced in Israel by Medical Link, part of the Baby Link group, which provides cutting-edge technology healthcare system and is held in Tel Aviv, Herzliya, Rishon Lezion, Haifa, Jerusalem, Beer Sheva and Karmiel. The test is available in the add-on basket of most health funds and private insurance companies and is for men over 50 who have a PSA level above 4 on a routine test and a referral from a urologist. To order a test, call the 24/7 National Call Center *5901 or go to https://isopsa.co.il/

Follow us on Telegram